PubRank

Hideho Okada

Author PubWeight™ 59.77‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 2011 2.06
2 Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci U S A 2009 1.94
3 Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res 2009 1.64
4 Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 2007 1.64
5 Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy 2012 1.55
6 EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 2005 1.49
7 Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 2008 1.46
8 Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 2002 1.42
9 Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res 2006 1.39
10 Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10. Cancer Res 2009 1.32
11 Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res 2010 1.28
12 MicroRNAs and STAT interplay. Semin Cancer Biol 2011 1.28
13 Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med 2004 1.26
14 Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res 2007 1.22
15 Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol 2010 1.19
16 Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 2003 1.18
17 GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. Cancer Res 2013 1.16
18 Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis. Methods Mol Biol 2007 1.14
19 Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res 2006 1.12
20 Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol Immunother 2010 1.12
21 Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. J Clin Invest 2011 1.10
22 miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. J Transl Med 2010 1.07
23 Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. J Immunol 2008 1.01
24 Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors. Cancer Gene Ther 2005 1.01
25 Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol 2005 0.98
26 Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. J Transl Med 2007 0.97
27 Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer Immunol Immunother 2014 0.96
28 Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol 2010 0.95
29 Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Ther 2003 0.93
30 IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. J Immunother 2009 0.92
31 Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res 2007 0.92
32 IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit. Eur J Immunol 2008 0.89
33 Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother 2011 0.89
34 The characterization of tumor apoptosis after experimental radiosurgery. Stereotact Funct Neurosurg 2005 0.89
35 Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel) 2013 0.88
36 Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol 2012 0.87
37 Do we need novel radiologic response criteria for brain tumor immunotherapy? Expert Rev Neurother 2011 0.87
38 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery 2002 0.86
39 Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res 2011 0.86
40 Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development. Immunol Invest 2012 0.86
41 Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy. J Immunol 2007 0.86
42 IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. J Immunol 2005 0.85
43 Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. J Neurooncol 2003 0.84
44 LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clin Cancer Res 2013 0.84
45 Differential activity of interferon-α8 promoter is regulated by Oct-1 and a SNP that dictates prognosis of glioma. Oncoimmunology 2012 0.84
46 Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res 2002 0.83
47 Premetastatic soil and prevention of breast cancer brain metastasis. Neuro Oncol 2013 0.83
48 Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest 2017 0.82
49 Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy. J Neurooncol 2012 0.80
50 Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med 2012 0.80
51 Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. J Neurooncol 2015 0.80
52 In vivo intracellular oxygen dynamics in murine brain glioma and immunotherapeutic response of cytotoxic T cells observed by fluorine-19 magnetic resonance imaging. PLoS One 2013 0.79
53 Peptide vaccine therapy for childhood gliomas. Neurosurgery 2013 0.76
54 Ependymomas: development of immunotherapeutic strategies. Expert Rev Neurother 2013 0.76
55 Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus. Adv Virol 2012 0.75
56 895 Desferoxamine Protects T Cells from Glioblastoma Multiforme-mediated Apoptosis and Improves Cytolytic Activity of T Cells in Killing of Tumor Targets. Neurosurgery 2005 0.75
57 Immunotherapy for pediatric central nervous system tumors. Biol Blood Marrow Transplant 2009 0.75